{"id":34152,"date":"2023-09-28T11:22:59","date_gmt":"2023-09-28T09:22:59","guid":{"rendered":"https:\/\/www.oafifoundation.com\/salud-osea-y-vitamina-d-en-osteoporosis\/"},"modified":"2023-09-28T12:30:08","modified_gmt":"2023-09-28T10:30:08","slug":"salud-osea-y-vitamina-d-en-osteoporosis","status":"publish","type":"post","link":"https:\/\/www.oafifoundation.com\/ca\/salud-osea-y-vitamina-d-en-osteoporosis\/","title":{"rendered":"CAP\u00cdTOL 2. Salut \u00f2ssia i Vitamina D: Vitamina D en osteoporosi"},"content":{"rendered":"\n<ul class=\"wp-block-list\">\n<li>La osteopL&#8217;osteoporosi \u00e9s una malaltia metab\u00f2lica que afebleix l&#8217;arquitectura \u00f2ssia i redueix la densitat \u00f2ssia i la for\u00e7a resultant en un augment del risc de fractures<a id=\"_ednref1\" href=\"#_edn1\">[i]<\/a>.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Figura 1: Comparativa de l&#8217;estructura interna en l&#8217;os sa i en l&#8217;osteoporosi.<\/strong><\/h3>\n\n\n\n<p><\/p>\n\n\n\n<p>L&#8217;os sa t\u00e9 una estructura m\u00e9s compacta mentre que en l&#8217;osteoporosi es produeix una menor densitat \u00f2ssia.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img decoding=\"async\" width=\"250\" height=\"155\" src=\"https:\/\/www.oafifoundation.com\/wp-content\/uploads\/2023\/09\/Imagen-1-2-1.png\" alt=\"\" class=\"wp-image-34148\"\/><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Figura 2: S\u00edmptomes comuns de l&#8217;osteoporosi<\/strong><\/h3>\n\n\n\n<figure class=\"wp-block-image size-full\"><img decoding=\"async\" width=\"172\" height=\"261\" src=\"https:\/\/www.oafifoundation.com\/wp-content\/uploads\/2023\/09\/Imagen-2-1.png\" alt=\"\" class=\"wp-image-34142\"\/><\/figure>\n\n\n\n<p>L&#8217;osteoporosi \u00e9s una malaltia molt freq\u00fcent i s&#8217;estima que a Europa hi ha 27,6 milions de persones que la sofreixen. Una de les principals conseq\u00fc\u00e8ncies de l&#8217;osteoporosi s\u00f3n les anomenades fractures osteopor\u00f2tiques, que es produeixen en aquests pacients fins i tot amb petits cops o caigudes. Aquestes fractures s\u00f3n molt freq\u00fcents i poden arribar a afectar 1\/3 de dones i 1\/5 d&#8217;homes majors de 50 anys <a id=\"_ednref1\" href=\"#_edn1\">[i]<\/a>.<\/p>\n\n\n\n<p>A nivell mundial l&#8217;osteoporosi afecta a uns 200 milions de persones i s&#8217;associa a 9 milions de fractures anuals<a id=\"_ednref1\" href=\"#_edn1\">[i]<\/a> i s&#8217;estima que l&#8217;any 2050 les es poden produir 21 milions de fractures de maluc anuals per aquesta causa<a id=\"_ednref2\" href=\"#_edn2\">[ii]<\/a>.<\/p>\n\n\n\n<p>La defici\u00e8ncia de&nbsp;VD&nbsp;\u00e9s un dels factors que contribueixen al desenvolupament de l&#8217;osteoporosi. Quan la concentraci\u00f3 de&nbsp;VD&nbsp;\u00e9s inferior a 20&nbsp;ng\/ml&nbsp;es produeix un augment del risc de fractures femorals i de fractures no-vertebrals en pacients majors i dones postmenopausa<a id=\"_ednref1\" href=\"#_edn1\">[i]<\/a><a id=\"_ednref2\" href=\"#_edn2\">[ii]<\/a>.<\/p>\n\n\n\n<p>Les persones majors s\u00f3n altament&nbsp;vulverables&nbsp;a les fractures per osteoporosis i fragilitat el que suposa una alta c\u00e0rrega sanit\u00e0ria i econ\u00f2mica. L&#8217;impacte d&#8217;aquestes fractures, especialment la de maluc, \u00e9s enorme<a id=\"_ednref1\" href=\"#_edn1\">[i]<\/a> <a id=\"_ednref2\" href=\"#_edn2\">[ii]<\/a> <a id=\"_ednref3\" href=\"#_edn3\">[iii]<\/a> <a id=\"_ednref4\" href=\"#_edn4\">[iv]<\/a> <a id=\"_ednref5\" href=\"#_edn5\">[v]<\/a>.:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Un 30% dels pacients es converteixen en discapacitats permanents,<\/li>\n\n\n\n<li>Un 40% perden l&#8217;habilitat de caminar de manera independent<\/li>\n\n\n\n<li>Un 80% es converteixen en dependents per a les activitats di\u00e0ries despr\u00e9s de la fractura<\/li>\n\n\n\n<li>I produeixen un 20% d&#8217;exc\u00e9s de mortalitat a 1 any<\/li>\n<\/ul>\n\n\n\n<p>Com hem vist, la defici\u00e8ncia de&nbsp;VD&nbsp;s&#8217;associa a una pitjor funci\u00f3 muscular, menor densitat \u00f2ssia i, per tant, major risc de caigudes. De fet, en els estudis s&#8217;ha vist que, en els pacients amb osteoporosis i fractura per fragilitat, incloent-hi la fractura de maluc, hi ha una alta prevalen\u00e7a de defici\u00e8ncia de VOST\u00c8<a id=\"_ednref1\" href=\"#_edn1\">[i]<\/a> <a id=\"_ednref2\" href=\"#_edn2\">[ii]<\/a>.<\/p>\n\n\n\n<p>La&nbsp;VD&nbsp;no sols redueix el risc de caigudes, sin\u00f3 que tamb\u00e9 millora la curaci\u00f3 de la fractura, en facilitar els processos de regeneraci\u00f3 \u00f2ssia, tal com s&#8217;ha vist en diversos estudis<a id=\"_ednref3\" href=\"#_edn3\">[iii]<\/a>.<\/p>\n\n\n\n<p>La suplementaci\u00f3 amb&nbsp;VD, per tant, forma part del tractament b\u00e0sic de l&#8217;osteoporosi i aix\u00ed est\u00e0 reconegut en les guies de diverses societats cient\u00edfiques. Per exemple, la&nbsp;SIMMONS<a id=\"_ftnref1\" href=\"#_ftn1\">[1]<\/a> va recomanar el 2022<a id=\"_ednref1\" href=\"#_edn1\">[i]<\/a> aconseguir nivells \u00f2ptims de&nbsp;VD&nbsp;en sang d&#8217;entre 20-50&nbsp;ng\/ml&nbsp;i suplementar, quan sigui necessari, amb&nbsp;colecalciferol&nbsp;entre 800 i 2.000&nbsp;UI&nbsp;al dia. Per la seva part la&nbsp;ESCEO<a id=\"_ftnref2\" href=\"#_ftn2\">[2]<\/a>, tamb\u00e9 el 2022<a id=\"_ednref2\" href=\"#_edn2\">[ii]<\/a> recomana suplementar amb&nbsp;VD&nbsp;entre 200 i 2.000&nbsp;UI&nbsp;al dia per a aconseguir almenys 20&nbsp;ng\/ml.<\/p>\n\n\n\n<p>[1] (Societat d&#8217;osteoporosi, metabolisme mineral i malalties \u00f2ssies)<\/p>\n\n\n\n<p>[2] (Societat Europea per a aspectes cl\u00ednics i econ\u00f2mics de l&#8217;osteoporosi, osteoartritis i malalties&nbsp;musculo-esquel\u00e8tiques)<\/p>\n\n\n\n<p>[1] (Ag\u00e8ncia Europea de Seguretat Aliment\u00e0ria)<\/p>\n\n\n\n<p>Les recomanacions de la&nbsp;EFSA<a id=\"_ftnref1\" href=\"#_ftn1\">[1]<\/a> indiquen que en persones adultes la dosi de suplement de&nbsp;VD&nbsp;recomanada est\u00e0 entre 600 i un m\u00e0xim de 4.000&nbsp;UI&nbsp;al dia.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Conclusions<\/strong>:<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>La Vitamina D \u00e9s una hormona necess\u00e0ria per al correcte funcionament de diversos sistemes (sistema nervi\u00f3s, sistema immune) aix\u00ed com per al recanvi-mineralitzaci\u00f3 \u00f2ssia i l&#8217;adequada densitat dels ossos.<\/strong><\/li>\n\n\n\n<li><strong>La Vitamina D ajuda tamb\u00e9 a la funci\u00f3, massa i for\u00e7a muscular<\/strong><\/li>\n\n\n\n<li><strong>L&#8217;osteoporosi \u00e9s una malaltia freq\u00fcent que augmenta el risc de caigudes i fractures<\/strong><\/li>\n\n\n\n<li><strong>La Suplementaci\u00f3 amb&nbsp;VD&nbsp;pot ajudar a les persones amb osteoporosis pels seus beneficis en l&#8217;os i els m\u00fasculs, reduint el risc de caigudes i fractures.<\/strong><\/li>\n\n\n\n<li><strong>Les societats cient\u00edfiques recomanen la suplementaci\u00f3 amb&nbsp;VD&nbsp;als pacients amb osteoporosis per a aconseguir uns nivells \u00f2ptims.<\/strong><\/li>\n<\/ul>\n\n\n\n<p>Una dosi de 600 a 800&nbsp;UI&nbsp;al dia de&nbsp;VD&nbsp;\u00e9s adequada per a la majoria dels pacients per a mantenir uns nivells \u00f2ptims de VOST\u00c8 Aquesta dosi s&#8217;haur\u00e0 d&#8217;augmentar si \u00e9s necessari, per a aconseguir els nivells \u00f2ptims de&nbsp;VD&nbsp;en sang (entre 30-50&nbsp;ng\/ml)<\/p>\n\n\n\n<p><\/p>\n\n\n\n<p>Article cortesia de la&nbsp;<strong><a href=\"https:\/\/www.linkedin.com\/in\/dr-esperanza-regueras-2728b71\/?originalSubdomain=es\" target=\"_blank\" rel=\"noreferrer noopener\">Dra. Esperanza Regueras<\/a>.&nbsp;<\/strong>Farmac\u00e8utica i Doctora en Farm\u00e0cia.&nbsp;CEO&nbsp;i directora cient\u00edfica d&#8217;<a href=\"https:\/\/www.advantalpharma.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">Advantal Pharma.<\/a><\/p>\n\n\n\n<p><\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Bibliografia<\/h3>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p><a href=\"#_ftnref1\" id=\"_ftn1\">[1]<\/a> (Agencia Europea de Seguridad Alimentaria)<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p><a href=\"#_ftnref1\" id=\"_ftn1\">[1]<\/a> (Sociedad de osteoporosis, metabolismo mineral y enfermedades \u00f3seas)<\/p>\n\n\n\n<p><a href=\"#_ftnref2\" id=\"_ftn2\">[2]<\/a> (Sociedad Europea para aspectos cl\u00ednicos y econ\u00f3micos de la osteoporosis, osteoartritis y enfermedades musculo-esquel\u00e9ticas)<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p><a href=\"#_ednref1\" id=\"_edn1\">[i]<\/a> Bertoldo F, Cianferotti L, Di Monaco M, Falchetti A, Fassio A, Gatti D, Gennari L, Giannini S, Girasole G, Gonnelli S, Malavolta N, Minisola S, Pedrazzoni M, Rendina D, Rossini M, Chiodini I. Definition, Assessment, and Management of Vitamin D Inadequacy: Suggestions, Recommendations, and Warnings from the Italian Society for Osteoporosis, Mineral Metabolism and Bone Diseases (SIOMMMS). Nutrients. 2022 Oct 6;14(19):4148. doi: 10.3390\/nu14194148. PMID: 36235800; PMCID: PMC9573415.<\/p>\n\n\n\n<p><a href=\"#_ednref2\" id=\"_edn2\">[ii]<\/a> Chevalley T, Brandi ML, Cashman KD, Cavalier E, Harvey NC, Maggi S, Cooper C, Al-Daghri N, Bock O, Bruy\u00e8re O, Rosa MM, Cortet B, Cruz-Jentoft AJ, Cherubini A, Dawson-Hughes B, Fielding R, Fuggle N, Halbout P, Kanis JA, Kaufman JM, Lamy O, Laslop A, Yerro MCP, Radermecker R, Thiyagarajan JA, Thomas T, Veronese N, de Wit M, Reginster JY, Rizzoli R. Role of vitamin D supplementation in the management of musculoskeletal diseases: update from an European Society of Clinical and Economical Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) working group. Aging Clin Exp Res. 2022 Nov;34(11):2603-2623. doi: 10.1007\/s40520-022-02279-6. Epub 2022 Oct 26. PMID: 36287325; PMCID: PMC9607746.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p><a href=\"#_ednref1\" id=\"_edn1\">[i]<\/a> Bouillon R, Marcocci C, Carmeliet G, Bikle D, White JH, Dawson-Hughes B, Lips P, Munns CF, Lazaretti-Castro M, Giustina A, Bilezikian J (2019) Skeletal and extraskeletal actions of vitamin D: current evidence and outstanding questions. Endocr Rev 40:1109\u20131151<\/p>\n\n\n\n<p><a href=\"#_ednref2\" id=\"_edn2\">[ii]<\/a> Bischoff-Ferrari HA, Can U, Staehelin HB, Platz A, Henschkowski J, Michel BA, Dawson-Hughes B, Theiler R (2008) Severe vitamin D deficiency in Swiss hip fracture patients. Bone 42:597\u2013602<\/p>\n\n\n\n<p><a href=\"#_ednref3\" id=\"_edn3\">[iii]<\/a> Chevalley T, Brandi ML, Cavalier E, Harvey NC, Iolascon G, Cooper C, Hannouche D, Kaux JF, Kurth A, Maggi S, Maier G, Papavasiliou K, Al-Daghri N, Sosa-Henr\u00edquez M, Suhm N, Tarantino U, Reginster JY, Rizzoli R. How can the orthopedic surgeon ensure optimal vitamin D status in patients operated for an osteoporotic fracture? Osteoporos Int. 2021 Oct;32(10):1921-1935. doi: 10.1007\/s00198-021-05957-9. Epub 2021 May 20. PMID: 34013461; PMCID: PMC8134831.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p><a href=\"#_ednref1\" id=\"_edn1\">[i]<\/a> Schurch MA, Rizzoli R, Mermillod B, Vasey H, Michel JP, Bonjour JP (1996) A prospective study on socioeconomic aspects of fracture of the proximal femur. J Bone Miner Res 11:1935\u2013 1942<\/p>\n\n\n\n<p><a href=\"#_ednref2\" id=\"_edn2\">[ii]<\/a> Johnell O, Kanis JA (2004) An estimate of the worldwide preva- lence, mortality and disability associated with hip fracture. Osteoporos Int 15:897\u2013902<\/p>\n\n\n\n<p><a href=\"#_ednref3\" id=\"_edn3\">[iii]<\/a> Piscitelli P, Neglia C, Feola M, Rizzo E, Argentiero A, Ascolese M, Rivezzi M, Rao C, Miani A, Distante A, Esposito S, Iolascon G, Tarantino U (2020) Updated incidence and costs of hip frac- tures in elderly Italian population. Aging Clin Exp Res 32:2587\u2013 2593<\/p>\n\n\n\n<p><a href=\"#_ednref4\" id=\"_edn4\">[iv]<\/a> Pedersen AB, Ehrenstein V, Szepligeti SK, Lunde A, Lagerros YT, Westerlund A, Tell GS, Sorensen HT (2017) Thirty-five- year trends in first-time hospitalization for hip fracture, 1-year mortality, and the prognostic impact of comorbidity: a Danish nationwide cohort study, 1980-2014. Epidemiology 28:898\u2013905<\/p>\n\n\n\n<p><a href=\"#_ednref5\" id=\"_edn5\">[v]<\/a> Borgstrom F, Karlsson L, Ortsater G et al (2020) Fragility frac- tures in Europe: burden, management and opportunities. Arch Osteoporos 15:59<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p><a href=\"#_ednref1\" id=\"_edn1\">[i]<\/a> Aspenberg P, Johansson T. Teriparatide improves early callus formation in distal radial fractures. Acta Orthop. 2010;81(2):234\u20136. doi: 10.3109\/17453671003761946.<\/p>\n\n\n\n<p><a href=\"#_ednref2\" id=\"_edn2\">[ii]<\/a> Garnero P, Munoz F, Sornay-Rendu E, Delmas PD. Associations of vitamin D status with bone mineral density, bone turnover, bone loss and fracture risk in healthy postmenopausal women. The OFELY study. Bone. 2007;40(3):716\u201322. doi: 10.1016\/j.bone.2006.09.026<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p><a href=\"#_ednref1\" id=\"_edn1\">[i]<\/a> Johnell O., Kanis J.A. An Estimate of the Worldwide Prevalence and Disability Associated with Osteoporotic Fractures. Osteoporos. Int. 2006;17:1726\u20131733. doi: 10.1007\/s00198-006-0172-4.<\/p>\n\n\n\n<p><a href=\"#_ednref2\" id=\"_edn2\">[ii]<\/a> Pisani P., Renna M.D., Conversano F., Casciaro E., Di Paola M., Quarta E., Muratore M., Casciaro S. Major Osteoporotic Fragility Fractures: Risk Factor Updates and Societal Impact. World J. Orthop. 2016;7:171\u2013181. doi: 10.5312\/wjo.v7.i3.171.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p><a href=\"#_ednref1\" id=\"_edn1\">[i]<\/a> Kenkre JS, Bassett J. The bone remodelling cycle. Ann Clin Biochem. 2018 May;55(3):308-327. doi: 10.1177\/0004563218759371. Epub 2018 Mar 4. PMID: 29368538.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p><a href=\"#_ednref1\" id=\"_edn1\">[i]<\/a> Ryan JW, Anderson PH, Turner AG, Morris HA. Vitamin D activities and metabolic bone disease. Clin Chim Acta. 2013 Oct 21;425:148-52. doi: 10.1016\/j.cca.2013.07.024. Epub 2013 Jul 30. PMID: 23911750.<\/p>\n\n\n\n<p><strong>* <\/strong>Des d&#8217;&nbsp;<a href=\"https:\/\/www.oafifoundation.com\/ca\/qui-som\/\" data-type=\"link\" data-id=\"www.oafifoundation.com\">OAFI<\/a>&nbsp;recomanem seguir els consells,&nbsp;sempre&nbsp;sota supervisi\u00f3 del seu metge de confian\u00e7a.<\/p>\n\n\n\n<p>*Imatge que il\u00b7lustra l&#8217;article de <a href=\"http:\/\/Towfiqu Barbhuyda\" target=\"_blank\" rel=\"noreferrer noopener\">Towfiqu Barbhuyda<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Figura 1: Comparativa de l&#8217;estructura interna en l&#8217;os sa i en l&#8217;osteoporosi. L&#8217;os sa t\u00e9 una estructura m\u00e9s compacta mentre que en l&#8217;osteoporosi es produeix una menor densitat \u00f2ssia. Figura 2: S\u00edmptomes comuns de l&#8217;osteoporosi L&#8217;osteoporosi \u00e9s una malaltia molt freq\u00fcent i s&#8217;estima que a Europa hi ha 27,6 milions de persones que la sofreixen. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":34155,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[549,1362,962,1286,814,959,1282,1389,552],"tags":[1450,1288,1451,1452,1257,1453,1454,1258,1279,1467,1464,1394,1281,1455,1466,1468,1363,1465,1456],"class_list":["post-34152","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-amics-oafi","category-aecosar-ca","category-area-pacients","category-blog-ca","category-consells-sobre-salut-articular","category-dolor-ca","category-osteoporosi","category-osteoporosis-en-ca","category-recerca","tag-aecosar-ca","tag-artrosis-ca","tag-cuidado-de-los-huesos-ca","tag-estructura-osea-ca","tag-fundacion-oafi-ca","tag-huesos-ca","tag-huesos-sanos-ca","tag-investigacion-ca","tag-oafi-ca","tag-os-sa","tag-osteoporosi","tag-osteoporosis-ca","tag-salud-articular-ca","tag-salud-osea-ca","tag-salut-ossia","tag-salut-ossia-i-vitamina-d","tag-vitamina-d-ca","tag-vitamina-d-i-osteoporosi","tag-vitamina-d-y-osteoporosis-ca"],"_links":{"self":[{"href":"https:\/\/www.oafifoundation.com\/ca\/wp-json\/wp\/v2\/posts\/34152","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.oafifoundation.com\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.oafifoundation.com\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.oafifoundation.com\/ca\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.oafifoundation.com\/ca\/wp-json\/wp\/v2\/comments?post=34152"}],"version-history":[{"count":9,"href":"https:\/\/www.oafifoundation.com\/ca\/wp-json\/wp\/v2\/posts\/34152\/revisions"}],"predecessor-version":[{"id":34176,"href":"https:\/\/www.oafifoundation.com\/ca\/wp-json\/wp\/v2\/posts\/34152\/revisions\/34176"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.oafifoundation.com\/ca\/wp-json\/wp\/v2\/media\/34155"}],"wp:attachment":[{"href":"https:\/\/www.oafifoundation.com\/ca\/wp-json\/wp\/v2\/media?parent=34152"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.oafifoundation.com\/ca\/wp-json\/wp\/v2\/categories?post=34152"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.oafifoundation.com\/ca\/wp-json\/wp\/v2\/tags?post=34152"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}